KRAS and colorectal carcinoma: Treating cells with CBA-1 significantly inhibits the Wnt signaling pathway and hence inhibits CRC cell growth with APC or β-catenin mutations and APC or KRAS mutations, providing evidence that APC might be a direct target for CBA-1.